Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort

被引:0
作者
Alexandre Prieur
Andrew Harper
Momtafin Khan
Bérengère Vire
Dominique Joubert
Léa Payen
Karen Kopciuk
机构
[1] Biodena Care,Cancer Epidemiology and Prevention Research
[2] Alberta Health Services,Departments of Oncology, Mathematics and Statistics, Community Health Sciences
[3] Lyon Sud Hospital,undefined
[4] University of Calgary,undefined
来源
BMC Cancer | / 23卷
关键词
Breast cancer; Circulating progastrin; hPG; Prognostic biomarker; Recurrence; Survival;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 168 条
[1]  
Gamble P(2021)Determining breast cancer biomarker status and associated morphological features using deep learning Commun Med 1 14-34
[2]  
Jaroensri R(2010)Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance Clin Med Insights Oncol 4 15-3277
[3]  
Wang H(2019)Prognostic models for breast cancer: a systematic review BMC Cancer 19 230-95
[4]  
Tan F(2017)Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility Int J Mol Sci 18 363-1177
[5]  
Moran M(2010)Metastatic behavior of breast cancer subtypes J Clin Oncol 28 3271-43
[6]  
Brown T(2018)Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort BMC Cancer 18 171-52
[7]  
Taneja P(2011)Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer Cancer Res Treat 43 89-5280
[8]  
Maglic D(2013)Prognostic factors for patients with bone-only metastasis in breast cancer Yonsei Med J 54 1168-539
[9]  
Kai F(2020)The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients EBioMedicine 51 863-1568
[10]  
Zhu S(2022)hPG(80) (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors Cancers (Basel) 14 35-4477